cas2297-sup-0001-FigureS1.tifimage/tif76KFig. S1. Proliferation in cyclopamine-treated ASPC-1 (ASPC) and SUIT-2 (SUIT) pancreatic ductal adenocarcinoma (PDAC) cells showed dose-dependent decrease.
cas2297-sup-0002-FigureS2.tifimage/tif91KFig. S2. Viable cells number in cyclopamine (cyc)-treated and 5-fluorouracil (5-FU)/gemcitabine (gem)-treated cells was significantly higher than that in 5-FU/gemcitabine treated cells.
cas2297-sup-0003-FigureS3.tifimage/tif132KFig. S3. Cyclopamine treatment (cyclo) inhibits the induction of apoptosis in 5-fluorouracil (5-FU) and gemcitabine (Gem) but not cis-diamminedichloroplatinum (CDDP)-treated ASPC-1 (ASPC) and SUIT-2 (SUIT) pancreatic ductal adenocarcinoma (PDAC) cells under hypoxic conditions.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.